RxDoctor Payments Data

Daniel Adler, MD

Gastroenterology · New York, NYNPI 1407952104

Payments from drug & device makers

$1,155in general payments, 2019–2025

Across 40 payments — averaging $28.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Scientific Affairs, LLC$280
  • Johnson & Johnson$237
  • AbbVie$231
  • Braintree Laboratories, Inc.$126
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$110
  • QOL Medical, LLC$68
  • plus $103 from 5 others

What the payments were for

  • Food & beverage$1,14299%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,155 in reported general payments places this provider in the 35th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$104,076
Medicare patients
302
Services billed
650

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dexlansoprazole DrDexlansoprazole41$11,482
LinzessLinaclotide14$7,129
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates105$6,601
Famotidine386$3,879
Pantoprazole Sodium266$2,776
Mesalamine ErMesalamine14$2,441
Rabeprazole Sodium101$2,439
SutabSod Sulf/Pot Chloride/Mag Sulf13$2,058
ClenpiqSod Picosulf/Mag Ox/Citric Ac11$1,910
Sucralfate79$1,411
Dicyclomine Hcl88$1,139
Esomeprazole Magnesium23$325
Diclofenac Sodium ErDiclofenac Sodium11$319
Naratriptan Hcl12$300
Omeprazole22$208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$231$7,12914 claims
Braintree Laboratories, Inc.Sutab$126$2,05813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →